Clinical Trial Update: Managed Access Programs for ABL001, Asciminib

View source ↗

Summary

The update describes managed access programs for asciminib (ABL001). These programs are intended to provide patient access for chronic myeloid leukemia in chron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Chronic Phase

Drugs mentioned

• Asciminib (asciminib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia in Chronic Phase | Status: AVAILABLE